摘要
目的研究安罗替尼联合铜绿假单胞菌注射液对食管癌患者的临床疗效、生活质量、免疫功能、血清肿瘤标志物水平及毒副反应的影响。方法选取南京医科大学第四附属医院(南京市浦口医院)和江苏省中医院在2018年6月-2019年4月收治的60例食管鳞癌患者为研究对象。对照组30例患者接受安罗替尼口服治疗,观察组30例患者接受安罗替尼口服联合铜绿假单胞菌注射液治疗。比较两组患者的临床疗效、生活质量、免疫功能、血清肿瘤标志物水平及毒副反应发生率。结果对照组临床治疗客观缓解率为30%,观察组为37%,组间差异无统计学意义(P>0.05)。观察组生活质量改善率显著高于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者血清肿瘤标志物NSE、Cyfra21-1、SCC水平均较治疗前显著下降,且观察组血清Cyfra21-1、SCC水平明显低于对照组,差异均有统计学意义(P<0.05)。观察组主要免疫指标CD3^+、CD8^+、NK细胞活性均显著高于对照组,而白细胞减少、贫血等毒副反应的总发生率显著低于对照组,差异均有统计学意义(P<0.05)。结论安罗替尼联合铜绿假单胞菌注射液方案对于食管癌患者的临床疗效确切,免疫增强剂铜绿假单胞菌注射液有助于显著提高患者的生活质量和免疫功能,并降低毒副反应。
Objective To investigate the effects of anlotinib combined with Pseudomonas aeruginosa injection on clinical efficacy,quality of life,immune function,serum tumor marker levels and toxic side effects in esophageal squamous cancer patients.Methods Sixty esophageal cancer patients who were admitted to the Fourth Affiliated Hospital of Nanjing Medical University (Nanjing Pukou Hospital) and Jiangsu Provincial Hospital of Traditional Chinese Medicine between June 2018 and April 2019 were selected in this study.The control group received treatment with oral anlotinib,and the observation group received oral anlotinib plus Pseudomonas aeruginosa injection.The clinical efficacy,quality of life,improvement of immune function,serum tumor marker level and incidence of side effects were compared between the two groups.Results The objective response rate was 30% in the control group,and 37% in the observation group.There was no statistical difference between the two groups (P>0.05).The improvement rate of quality of life in the observation group was significantly higher than that of the control group (P<0.05).After treatment,the expression levels of serum tumor markers NSE,Cyfra21-1 and SCC in the two groups were significantly lower than those before treatment (P<0.05).The serum levels of Cyfra21-1 and SCC in the observation group were significantly lower than those of the control group after treatment (P<0.05).In addition,the activity of CD3^+,CD8^+ and NK cells in the observation group was significantly higher than that of the control group (P<0.05),and the overall incidence of toxic side effects including leukopenia and anemia was lower than that of the control group,and the difference was statistically significant (P<0.05).Conclusion Anlotinib combined with Pseudomonas aeruginosa injection could bring clinical benefit to the treatment of esophageal cancer patients.Pseudomonas aeruginosa injection could significantly improve immune function and the quality of life of patients,and reduce the side effects of tumor treatment.
作者
刘龙发
薛建辉
LIU Longfa;XUE Jianhui(Department of Gastroenterology,the Fourth Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu,210031,China;Department of Thoracic Surgery,Jiangsu Province Hospital of Chinese Medicine,Nanjing,Jiangsu,210029,China)
出处
《肿瘤药学》
CAS
2019年第6期905-911,共7页
Anti-Tumor Pharmacy
基金
南京市科技局课题(201715074)
关键词
食管癌
安罗替尼
铜绿假单胞菌注射液
疗效
安全性
Esophageal cancer
Anlotinib
Pseudomonas aeruginosa injection
Efficacy and safety
